Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOPE: Sacituzumab Tirumotecan + Toripalimab in Advanced Penile Squamous Cell Carcinoma
NCT07907861Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and toripalimab in penile squamous cell carcinoma (PSCC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Objective Response Rate up to 24 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantoripalimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT07907861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07907861.